Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000851

Drug Information
NameGemifloxacin
SynonymsBSPBio_002308; NCGC00178711-01; 210353-52-9; SB-265805; Gemifloxacin; CHEMBL430; BRD-A40787240-066-02-0; SB 265805; CID9571107; 7-(3-Aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid; LS-187779; Factiv; LB-20304; 204519-64-2; 210353-53-0; Factive; 7-(3-Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 210353-55-2; Gemifloxacin mesilate; 214346-11-9; LB 20304a; CHEBI:101853; 210353-56-3; 175463-14-6; 1,8-Naphthyridine-3-carboxylic acid, 7-(3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-; Gemifloxacin [INN]; Gemifloxacin (INN); 7-[3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1,8-Naphthyridine-3-carboxylic acid, 7-[(4Z)-3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-; D08012; LS-186992; Factiv (TN); LB 20304
Trade NameFactive
CompanyOscient Pharmaceuticals
IndicationBacterial infections
[ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104   ICD10: A00-A09, A15-A19, A20-A28, A30-A49, A65-A69, A70-A74, A75-A79]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)1
2(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1
H3,(H,26,27)/b22-14+
InChIKeyZRCVYEYHRGVLOC-HYARGMPZSA-N
Canonical SMILESCON=C1CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F    
Isomeric SMILESCO/N=C/1\CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F
Therapeutic ClassAntibacterial Agents
CAS NumberCAS 175463-14-6
FormulaC18H20FN5O4
PubChem Compound IDCID 9571107.
PubChem Substance IDSID 215182.
SuperDrug ATC IDJ01MA15
SuperDrug CAS ID175463146;
TargetDNA gyraseInhibitor[2]
DNA gyraseMultitarget[2]
DNA topoisomerase IVInhibitor[2]
DNA topoisomerase IVMultitarget[2]
Ref 1Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. To Reference
Ref 2Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2005 May;25(5):717-40. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543